Diabetes Diagnostics - Global Strategic Business Report
- Language: English
- 492 Pages
- Published: April 2012
- Region: World
Following the example of the US FDA's Orphan Drug Act established in 1983, some Asian countries have developed orphan drug legislations, such as Singapore's Orphan Drug Exemption to the Medicines Act and Japan's Orphan Drug Amendment to the Pharmaceutical Affairs Law.
While orphan drug laws in Asia may provide benefits for companies registering new drugs, such as marketing exclusivity, an expedited registration process, and a reduction in the number of clinical trials required, each registration process is unique and can pose a variety of challenges.
This report reviews the orphan drug regulations in 10 Asian countries and discusses various business issues related to orphan drugs in the region. Lists of approved orphan drugs in Japan and Korea as well as a list of orphan drug associations are also included.
Updates for 2012 include:
- Recent 2012 government approval list for orphan drugs in Taiwan
- Updated application forms and requirements in Japan, Taiwan, Korea, Hong Kong and China
- Latest orphan drug registration policies and regulations in Asia
- New information involving priority review and regulations in Asia
- Recent data involving orphan
READ MORE >
I. Introduction
A. Global Outlook on rare diseases
B. Development of Orphan Drug Legislation
C. Well-Known Rare Diseases
D. US FDA Contact Information
E. US Orphan Drug Associations
F. US FDA Orphan Drug Approvals
II. Overview of Asia
A. The Asian Economy
B. The Pharmaceutical Markets in Asia
III. Orphan Drugs in Asia
A. Do orphan drugs have potential in Asia?
B. Why seek orphan drug status?
IV. Issues to Consider Prior to Orphan Drug Registration
A. Introduction
B. Are treatment options already available in the country?
C. Is your drug superior to those already on the market?
D. Conclusion
V. Japan
A. Introduction
B. Ministry of Health, Labor and Welfare
C. Pharmaceuticals and Medical Devices Agency
D. Orphan Drugs in Japan
E. Health Authority Contact Information
F. Orphan Drug Associations
G. Orphan Drugs Approved in Japan
H. Orphan Drugs Designated in Japan
VI. Taiwan
A. Overview
B. Taiwanese Health Authorities
C. Health Insurance Scheme
D. Orphan Drugs in Taiwan
E. Health Authority Contact Information
F. Orphan Drug Associations
VII. Korea
A. Overview
B. Drug Registration Overview
C. Orphan Drugs in Korea
D. Health Authority Contact Information
E. Orphan Drug Associations
F. Orphan Drugs Approved in Korea
VIII. Hong Kong
A. Overview
B. Hong Kong Health Authority
C. Orphan Drugs In Hong Kong
D. Health Authority Contact Information
IX. China
A. Overview
B. Pharmaceutical Market
C. China Health Authority
D. Drug Registration Process
E. Drug Pricing
F. Orphan Drugs in China
G. Health Authority Contact Information
X. Singapore
A. Overview
B. Singapore Health Authority
C. Orphan Drug Definition and Legislation
D. Health Authority Contact Information
XI. Southeast Asia Introduction
A. Overview
B. Drug Registration Requirements for Southeast Asia
XII. Philippines
A. Overview
B. Philippines Health Authority
C. Orphan Drug Registration Process
D. Health Authority Contact Information
XIII. Malaysia
A. Overview
B. Malaysia Health Authority
C. Drug Registration Overview
D. Health Authority Contact Information
XIV. Thailand
A. Overview
B. Drug Registration Overview
C. Orphan Drug Summary
D. Health Authority Contact Information
XV. Vietnam
A. Overview
B. Drug Registration Overview
C. Health Authority Contact Information
D. Orphan Drug Associations
XVI. Sales and Marketing of Orphan Drugs
A. Introduction
B. Preparing a Sales Forecast
C. In-country Support
D. Distribution
XVII. Conclusion
| Format | Properties | |
|---|---|---|
| Hard Copy | A printed copy of the report will be shipped to you. |